Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as our drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as “generics,” in addition to the development and marketing of branded products. We operate in two segments, referred to as the “Global Pharmaceuticals Division” (“Global Division”) and the “Impax Pharmaceuticals Division” (“Impax Division”). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of our generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. ... More ...
Analyst Info |
|
| Annual EPS Est: | $1.91 |
| Quarterly EPS Est: | 0.02 |
| PEG Ratio: | 4.37 |
|
Mean Recommendation: View Summary / View All |
2.58 |
Data is provided by Zacks Investment Research
